S&P 500 Financials Sector SEC Filings — March 09, 2026

09-03-2026

Netlist, Inc. entered into the First Amendment to Lease with University Research Park LLC, dated March 4, 2026, as reported in this 8-K filing under Item 1.01 (Entry into a Material Definitive Agreement). The amendment is attached as Exhibit 10.1. The filing was signed by Gail M. Sasaki, Executive Vice President and Chief Financial Officer, on March 9, 2026.

09-03-2026

Product revenue grew significantly to $72.2M from $7.3M YoY while supply agreement revenue increased substantially, but total revenue declined 5% YoY to $84.3M due to an 88% drop in collaboration revenue to $9.7M. Operating expenses surged 186% to $263.7M, driven by a 221% rise in SG&A to $230.1M, leading to a net loss of $171.3M versus $8.0M profit in 2024. Stockholders' equity fell to $114.3M from $256.8M amid heavy operating cash use of $170.9M.

• ·Net cash used in operating activities: $170.9M in 2025 vs provided $13.5M in 2024.
• ·Cash and equivalents decreased by $9.5M net in 2025.
• ·Total assets: $327.7M at Dec 31 2025 (down from $351.2M).
• ·Accumulated deficit: $294.6M at Dec 31 2025 (up from $123.3M).
• ·Term loans, net: $96.4M at Dec 31 2025 (none in 2024).
• ·Auditor focus: rebates estimation as key audit matter.

09-03-2026

Brand Engagement Network, Inc. completed the third and final closing of a previously announced $1.518M private placement with Ben Capital Fund I, LLC on March 9, 2026, receiving the final $506K installment. The transaction involved the sale of 24,000 shares of common stock at $63.25 per share, funded in three equal installments. No other material changes or performance metrics were reported.

• ·Shares sold at $63.25 per share
• ·Securities offered under Section 4(a)(2) exemption of the Securities Act of 1933
• ·Previously disclosed in 8-K filed January 30, 2026

09-03-2026

Aureus Greenway Holdings Inc. (AGH) entered into an Agreement and Plan of Merger dated March 8, 2026, with Autonomous Power Corporation, Aureus Merger Sub Inc., and Andrew Fox as Stockholder Representative, under which AGH's wholly-owned subsidiary will merge with Autonomous Power, surviving as a wholly-owned subsidiary of AGH. The Parent Board and Company Board unanimously approved the transaction, with requisite stockholder consents to be delivered promptly, and the merger is intended to qualify as a tax-free reorganization under Section 368(a) of the Code. AGH will amend its charter to change its name to Powerus Corporation effective at closing.

• ·Filing Date: March 09, 2026
• ·Agreement Date: March 8, 2026
• ·Closing to occur on second Business Day after satisfaction of conditions in Article VI
• ·Simultaneous execution of Lock-Up Agreements (Exhibit A) by Company Significant Holders and Leak-Out Agreements (Exhibit B) by Parent Significant Holders, effective at Closing
• ·Parent name change to Powerus Corporation via Parent Charter Amendment

09-03-2026

Innovation Beverage Group Limited filed a preliminary F-1 registration statement on March 9, 2026, for a proposed public offering of up to $15,000,000 through up to 4,166,667 Ordinary Units (each consisting of one Ordinary Share, one Series A Warrant, and one Series B Warrant) or Pre-Funded Units, with Aegis Capital Corp. as placement agent. The prospectus incorporates prior filings including Form 8-A from September 16, 2024, and details historical unregistered securities issuances from 2023-2024 totaling various small share grants and private placements exempt under Sections 4(a)(2), Reg D, Reg S, and Rule 701. No financial performance metrics or period-over-period comparisons are provided in this filing.

• ·Historical unregistered issuances include a 5:1 share consolidation in 2025 affecting share counts.
• ·F-1 amendments filed multiple times from February 28, 2025, through February 24, 2026.
• ·Company address: 29 Anvil Road, Seven Hills, NSW 2147, Australia.

09-03-2026

American Strategic Investment Co. (NYSE: NYC) filed an 8-K on March 9, 2026, under Items 7.01 and 9.01, disclosing a press release dated March 9, 2026, attached as Exhibit 99.1. The information in the filing and exhibit is furnished pursuant to Regulation FD and not deemed filed under the Exchange Act. The report was signed by Michael LeSanto, Chief Financial Officer.

• ·Securities registered: Class A common stock ($0.01 par value, NYSE: NYC); Class A Preferred Stock Purchase Rights (NYSE).
• ·Principal executive offices: 222 Bellevue Ave, Newport, Rhode Island 02840.
• ·Company details: Maryland incorporation, Commission File No. 001-39448, EIN 46-4380248.

09-03-2026

BETA Technologies reported FY2025 revenues of $35.6M, up 136% YoY from $15.1M, driven by product and service growth including motors and engineering contracts; Q4 revenues reached $11.1M, up 151% YoY from $4.4M. However, net loss widened significantly to ($745.9M) from ($275.6M) YoY due to elevated R&D ($259.9M, +26%) and G&A ($138.5M, +83%) expenses, with Adjusted EBITDA loss expanding to ($304.1M) from ($243.3M). Cash position strengthened to $1.71B post-IPO, supporting a $3.5B aircraft backlog, though 2026 guidance projects modest revenue growth to $39-43M amid continued EBITDA losses of ($305-395M).

• ·Product revenues FY2025: $12.4M (up from $1.9M YoY); Service revenues: $23.2M (up from $13.2M YoY).
• ·FY2026 guidance: Revenues $39-43M; Adjusted EBITDA ($305M to $395M).
• ·H500A electric engine on track for FAA type certification in H1 2026.
• ·$4M project funding from U.S. Army for autonomous flight capabilities.

09-03-2026

PharmaCyte Biotech, Inc. (PMCB) filed a DEF 14A proxy statement on March 9, 2026, for its virtual annual stockholder meeting on March 30, 2026, at 11:00 a.m. ET, with record date January 30, 2026. As of the record date, 10,735,649 common shares were outstanding, plus 2,677,093 as-converted votes from Series C Preferred Stock. The filing includes pay versus performance disclosures for executives Joshua N. Silverman and Kenneth L. Waggoner covering fiscal years ended April 30, 2023, 2024, and 2025, though specific compensation values are not detailed in the provided content.

• ·Annual meeting held virtually; access via http://www.web.viewproxy.com/PMCB/2026
• ·Fiscal year end: April 30
• ·Transfer agent: Equiniti Trust Company, LLC
• ·Business address: 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169

09-03-2026

American Resources Corporation (AREC) filed its 2026 DEF 14A Proxy Statement for the Annual Shareholder Meeting on April 15, 2026, seeking shareholder approval to elect its five current director nominees for one-year terms and to ratify GreenGrowth CPAs as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date is February 17, 2026, with 106,925,819 shares of common stock outstanding. The Board unanimously recommends voting FOR both proposals, with no financial performance metrics or period-over-period comparisons disclosed in the filing.

• ·Annual Meeting location: 12115 Visionary Way, Suite 174, Fishers, Indiana 46038; in-person only, no virtual participation option.
• ·Board Diversity (as of January 1, 2026): 1 female, 4 male directors; 1 Hispanic or Latinx director.
• ·Voting methods: Internet at www.AALvote.com/AREC or www.FCRvote.com/AREC, telephone at 1-866-804-9619, mail, or in-person.
• ·Directors elected by plurality vote; abstentions and broker non-votes do not affect outcome.

09-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed a Form 8-K on March 9, 2026, under Items 8.01 and 9.01, announcing the issuance of a press release titled 'The Top 20 Things You Probably Did Not Know About AITX and RAD', attached as Exhibit 99.1. The information is furnished and explicitly stated as not material or filed for liability purposes under the Exchange Act.

09-03-2026

This Rule 425 filing from Nuveen Municipal High Income Opportunity Fund (NMZ) urges shareholders of Nuveen New Jersey Quality Municipal Income Fund to vote 'FOR' all proposals by March 19, 2026, with less than 3 days remaining as of the March 9, 2026 filing date. The Board strongly recommends approval, stating it is in the best interest of the Fund, and emphasizes that every vote counts to achieve sufficient participation. Proxy solicitation support is available via toll-free number from Computershare.

• ·Commission File No. for NMZ: 333-290590
• ·Commission File No. for Nuveen New Jersey Quality Municipal Income Fund: 811-09455
• ·Voting support hours: 9:00 am to 11:00 pm Eastern Time weekdays; Noon to 6:00 pm Eastern Time Saturday
• ·Contact address: 51 West 52nd Street, 6th Floor, New York, NY 10019

09-03-2026

Pantages Capital Acquisition Corp, a blank check company, reported total assets of $90.4M as of Dec 31, 2025, up from $87.2M prior year, driven by growth in the Trust Account to $90.1M (+4.1%) from interest income of $3.6M. However, cash declined sharply to $0.19M from $0.53M (-65%), operating losses widened to $1.02M from $0.35M, and shareholders' deficit deepened to $(1.38M) from $(0.36M). Net income turned positive at $2.55M (vs prior loss of $0.09M), primarily from Trust interest, with EPS of $0.23.

• ·Prepaid expenses declined to $87,377 from $122,434.
• ·Accounts payable and accrued expenses decreased to $78,128 from $121,039.
• ·Due to related parties minimal at $294 (down from $33,521).
• ·Basic and diluted EPS for redeemable Class A shares: $0.23 in 2025 vs $(0.03) in 2024.

09-03-2026

Hooker Furnishings Corporation (HOFT) filed a Form 8-K on March 9, 2026, reporting an event dated March 5, 2026, under Item 8.01 Other Events, announcing the issuance of a press release on March 6, 2026, attached as Exhibit 99.1. The filing was signed by C. Earl Armstrong III, Chief Financial Officer and Senior Vice-President - Finance. No financial or operational details from the press release are provided in the filing body.

• ·Date of earliest event reported: March 5, 2026
• ·Press release issuance date: March 6, 2026
• ·Securities: Common Stock, no par value (HOFT) on NASDAQ Global Select Market

09-03-2026

Tri-County Financial Group, Inc. reported total assets of $1.6B, up 3.7% YoY, with loans growing 3.0% to $1.3B and net income surging 31.0% to $13.7M driven by 16.8% higher net interest income and 10.2% noninterest income growth. However, nonperforming loans ratio rose to 0.43% from 0.33%, credit loss expense flipped to $0.7M from a $1.3M recovery, and allowance coverage of nonperforming loans declined to 264.9% from 346.9%. Financial ratios improved with ROA at 0.88% (up from 0.68%) and ROE at 9.09% (up from 7.45%), but noninterest expense increased 4.9%.

• ·Return on average assets improved to 0.88% from 0.68%; Return on average equity to 9.09% from 7.45%.
• ·Net interest margin expanded to 3.40% from 2.96%.
• ·Tier 1 leverage capital ratio of subsidiary Bank at 10.51% (up from 10.30%); Risk-based total capital ratio at 14.91% (up from 14.50%).
• ·Mortgage banking income up 13.4% to $11.3M; Insurance services up 24.6%.

09-03-2026

Cumberland Pharmaceuticals Inc. reported net revenues of $44.5M for the year ended December 31, 2025, up 17.6% YoY from $37.9M, driven by strong growth in Sancuso (+32% to $11.9M), Vibativ (+33% to $9.5M), new Talicia ($3.3M), and Other (+211% to $4.1M). However, Kristalose revenues declined 31% to $10.5M and Caldoror fell 6% to $4.7M; operating loss narrowed to $2.8M from $6.4M but remained negative, with net loss at $2.9M versus $6.4M prior year. Cash and equivalents decreased to $11.4M from $18.0M, working capital dropped sharply to $0.3M from $4.8M, and current ratio slipped to 1.0x from 1.2x.

• ·Cash from operating activities improved to $4.9M in 2025 from -$0.6M in 2024.
• ·Vibativ contribution margin: $7.6M in 2025 vs. $3.6M in 2024.
• ·Sancuso contribution margin: $7.2M in 2025 vs. $4.4M in 2024.
• ·Revolving line of credit availability increased to $9.8M from $4.7M.

09-03-2026

Future Money Acquisition Corporation, a Cayman Islands-incorporated blank check company (SIC 6770), filed Amendment No. 2 to its Form S-1 registration statement (No. 333-291996) on March 6, 2026, as an exhibits-only update with no changes to the main prospectus. New exhibits include specimen unit/share certificates, legal opinions, auditor consents, and a filing fee table, while previously filed exhibits remain unchanged. The filing advances the proposed IPO, with sales to commence as soon as practicable post-effectiveness.

• ·Principal executive offices: 475 Brannan St, San Francisco, CA 94107; Phone: +1 6479860980
• ·Agent for service: Cogency Global Inc., 122 East 42nd Street, 18th Floor, New York, NY 10168
• ·Key exhibit dates: Securities Subscription Agreement (Nov 24, 2025); Promissory Note (Oct 2, 2025, as amended)
• ·Registrant status: Non-accelerated filer, smaller reporting company, emerging growth company
• ·Newly filed exhibits (**): 1.1 (Underwriting Agreement), 4.1 (Unit Cert.), 4.2 (Share Cert.), 5.1 (Harney Opinion), 23.1 (HYYH Consent)

09-03-2026

EVgo Inc.'s 10-K filing highlights operational strategies including efficient charging equipment procurement, technology-enabled products like Autocharge+ and the EVgo Public Network to enhance customer experience and efficiencies, and diversified charging revenue streams from retail, commercial fleets, and OEM partnerships. However, it emphasizes significant risks from evolving regulations such as the OBBBA terminating the 30C income tax credit, potential policy changes, inflation driving up costs, and U.S. tax law modifications that could adversely impact financial condition. These factors underscore a challenging regulatory and economic environment amid efforts to maintain market leadership in EV charging infrastructure.

• ·Filing Date: March 09, 2026
• ·Risks include termination of 30C income tax credit via OBBBA and potential tariff/sanctions changes

09-03-2026

Melar Acquisition Corp. I/Cayman, a blank check company with no operating history or revenues, filed its 10-K on March 9, 2026, for the year ended December 31, 2025, disclosing risks related to completing an initial Business Combination, including the proposed Everli Business Combination which could result in substantially all assets and revenue in a foreign country. The filing details potential Working Capital Loans up to $1.5M from the Sponsor or affiliates, convertible into warrants, and lists beneficial owners via Schedule 13G filings from entities like LMR Partners, AQR, Wolverine (holding 926,328 Public Shares as of Sep 30, 2025), Mizuho, and others. No operating performance metrics are provided, consistent with SPAC status.

• ·Company inception: March 11, 2024
• ·Financial statements compare year ended December 31, 2025 to period from inception through December 31, 2024
• ·Risk of negative interest rates on Trust Account investments potentially reducing per-share redemption value
• ·Schedule 13G filing dates: November 14, 2024 (LMR, AQR); August 14, 2025 (Meteora); October 10, 2025 (Wolverine); November 13, 2025 (Mizuho); February 11, 2026 (W.R. Berkley); March 21, 2025 (Barclays)

09-03-2026

Sphere 3D Corp. reported FY2025 revenue of $11.2 million, down 32.5% YoY from $16.6 million in 2024, primarily due to the April 2024 Bitcoin halving and equipment replacement. Operating costs and expenses decreased 12.6% to $33.2 million, with G&A expenses falling 33% to $8.3 million; however, net loss widened to $21.5 million from $9.5 million amid lower investment gains and higher impairments. The company mined 111.6 Bitcoin, held 37.3 Bitcoin at year-end, improved fleet efficiency to below 19.0 J/TH from 27.1 J/TH, and announced a merger with Cathedra Bitcoin.

• ·Impairment of property and equipment increased to $7.2M in FY2025 from $1.1M in FY2024.
• ·Cash and cash equivalents decreased to $3.7M as of Dec 31, 2025 from $5.4M as of Dec 31, 2024.
• ·Investment in equity securities dropped to $0 from $7.5M as of Dec 31, 2024.

09-03-2026

Great Lakes Dredge & Dock Corp (GLDD) reported strong FY2025 results with contract revenues increasing 16.5% YoY to $888M from $763M in 2024, gross profit up 26.7% to $203M, operating income up 37.7% to $128M, and net income surging 28.4% to $73M (diluted EPS $1.08 vs $0.84). Total assets grew modestly 2.4% to $1.286B, equity rose 15.3% to $517M, and operating cash flow jumped 252% to $247M; however, accounts receivable declined sharply 40.5% to $70M, current assets fell 17.5% to $217M, and total liabilities decreased due to debt reduction but deferred taxes rose 31.7%. Capex increased to $147M amid property and equipment net up 14.2% to $803M, with $12M in common stock repurchases.

• ·Long-term debt decreased 15.6% to $378M from $448M.
• ·Deferred income taxes increased 31.7% to $104M from $79M.
• ·Cash paid for interest $30M in 2025 vs $30M in 2024 (flat).
• ·Loss on extinguishment of debt $11M in 2025.
• ·Repaid $100M Second Lien Term loan in 2025.

09-03-2026

Longeveron Inc. reported the immediate resignation of Board member and Audit Committee chairman Richard Kender on March 3, 2026, due to his new role as Executive Chairman and Interim CEO at Seres Therapeutics, resulting in temporary non-compliance with Nasdaq Listing Rule 5605(c)(2)(A) for lacking three independent audit committee members and a financial expert. On March 4, 2026, the company appointed existing Board member Dr. Roger Hajjar to the Audit Committee, restoring the minimum three independent members but still without a financial expert. Longeveron plans to appoint or elect a qualified independent audit committee financial expert within the 180-day cure period or at the next annual shareholders' meeting.

• ·Resignation not due to any disagreement with company operations, policies, practices, management, or Board.
• ·Seres Therapeutics announced Kender's new role on March 2, 2026.

09-03-2026

Xanadu Quantum Technologies Inc. announced a $2.0M ARPA-E grant to develop a quantum simulation platform for next-generation batteries, in partnership with the University of Chicago, as part of the QC3 program. This builds momentum ahead of its business combination with Crane Harbor Acquisition Corp., expected to provide $500M in gross proceeds ($225M from trust assuming no redemptions, $275M PIPE), with NewCo listing on Nasdaq and TSX. No financial declines or flat metrics reported; the grant supports a 3-year project targeting 100x faster simulations versus classical methods.

• ·3-year project duration focused on defect formations in battery materials using X-ray absorption spectroscopy and reaction rate algorithms
• ·Project goal: 100x reduction in simulation runtime vs. classical methods
• ·Form F-4 registration statement filed with SEC for the business combination

09-03-2026

SharpLink Gaming reported total revenue of $28.1M for FY 2025, up 666% YoY from $3.7M, driven by $25.6M in new staking revenue, though affiliate marketing revenue declined 33% YoY to $2.5M. The company posted a massive net loss of $734.6M, primarily due to $616.2M unrealized losses on crypto assets and $140.2M impairment on LsETH holdings, contrasting with a $10.1M profit in FY 2024 which included discontinued operations income. LsETH holdings stood at a carrying value of $500.9M (204,409 units) after acquisitions funded by PIPE and ATM offerings, with original cost basis of $624.7M.

• ·ETH traded below $1,472 and above $4,821 per ETH on Coinbase in 2025.
• ·LsETH acquisitions: 236,983 units at approx. average purchase price per LsETH of $3.
• ·Adopted ASU 2023-08 effective Jan 1, 2025 for fair value accounting of ETH holdings.
• ·No long-term debt on balance sheet.
• ·Stock-based compensation, related party: $16.5M in 2025.

09-03-2026

On February 27, 2026, the Board of Directors of Norris Industries, Inc. accepted a capital contribution from Mr. Patrick Norris and his affiliates consisting of their 1,000,000 currently issued and outstanding shares of preferred stock. These shares will be cancelled and returned to the status of authorized but unissued preferred stock. No financial performance metrics or period comparisons were disclosed.

• ·Date of Report (earliest event): February 28, 2026
• ·Filing signed: March 4, 2026
• ·SEC Filing Date: March 09, 2026

09-03-2026

Mission Produce, Inc. (AVO) filed an S-4 registration statement on March 9, 2026, as a joint proxy statement/prospectus for a proposed two-step merger acquisition of Calavo Growers, Inc., involving wholly-owned subsidiaries Cantaloupe Merger Sub I, Inc. and Cantaloupe Merger Sub II, LLC, pending shareholder approvals at virtual special meetings. As of March 6, 2026, Mission Produce has 70,846,364 shares outstanding (30.85% beneficially owned by directors and executives, who intend to vote in favor), while Calavo has 17,874,079 shares outstanding; however, the filing prominently highlights substantial risks related to the mergers, Mission Produce, Calavo, and the combined company.

• ·Mission Produce Special Meeting to vote on Share Issuance Proposal and Adjournment Proposal; requires majority of voting power present.
• ·Calavo Special Meeting to vote on Merger Agreement Proposal (majority of outstanding shares), Merger-Related Compensation Proposal (majority of shares represented), and Adjournment Proposal.
• ·Calavo engaged Georgeson Advisory as proxy solicitor.

09-03-2026

908 Devices Inc. reported total revenue of $56.2M for the year ended December 31, 2025, up 17.7% YoY from $47.7M in 2024, driven by strong growth in recurring revenue (+22.0% to $19.4M), U.S. state/local sales (+38.2% to $24.2M), rest of world (+21.4% to $14.4M), and global pharmaceutical/industrial (+98.7% to $3.0M). However, U.S. federal and defense revenue declined 13.6% to $14.5M, contract revenue fell 11.4% to $0.1M, and device sales growth slowed to 15.7% at $36.7M, amid risks from long sales cycles and heavy reliance on government contracts.

• ·Over 700 customers including major government institutions.
• ·Risks include long and unpredictable sales cycles, heavy dependence on U.S. government orders, and potential impacts from government contracting/fiscal policy changes.

09-03-2026

Cross Country Healthcare's 2025 revenue declined 21.6% YoY to $1.05B from $1.34B, with Nurse and Allied Staffing revenue dropping to $863M amid 17.3% fewer FTEs (6,784 vs 8,205) and 8.5% lower revenue per FTE/day ($346 vs $378), while Physician Staffing revenue fell slightly to $192M on 14% fewer days filled despite 12.1% higher revenue per day ($2,274 vs $2,029). Net loss widened dramatically to $95M from $15M, driven by $78M impairment charges (up from $3M) and operating loss of $84M (vs $17M). Total assets shrank to $449M from $589M, reflecting significant goodwill impairment.

• ·Cash and equivalents increased to $109M from $82M.
• ·Goodwill decreased to $64M from $135M.
• ·Corporate overhead declined to $61M from $69M.
• ·Contribution income for Physician Staffing rose slightly to $16M from $15M.

09-03-2026

Battalion Oil Corporation entered into a definitive agreement to raise approximately $15 million gross ($14.1 million net after fees) through a private placement of common stock at $5.50 per share and/or prefunded warrants with a new institutional investor, with Roth Capital Partners as sole placement agent. The offering is expected to close on March 4, 2026, subject to customary conditions, with proceeds intended for working capital and general corporate purposes. The company also noted an increase in average oil production of approximately 1,200 net barrels per day in January compared to December.

• ·Expected closing date: March 4, 2026, subject to customary conditions
• ·Company to file resale registration statement on Form S-3 within 20 days of closing
• ·Securities offered in unregistered private placement under Securities Act exemptions
• ·Oil production increase of approximately 1,200 net barrels per day (January vs. December)

09-03-2026

Bunker Hill Mining Corp. closed a brokered LIFE offering of 150,808,332 units at C$0.18 for gross proceeds of C$27,145,500, a concurrent non-brokered private placement of 8,926,668 units for C$1,606,800, and a warrant exercise for C$5,000,000, totaling C$33,752,300 in aggregate proceeds. Net proceeds will fund working capital for the ramp-up of the Bunker Hill Mine to commercial production, exploration, and general corporate purposes. No declines or flat metrics reported; however, the offering involves dilution to existing shareholders and includes minor insider participation of 300,000 units.

• ·Each LIFE Unit includes one Common Share and one Warrant exercisable at C$0.30 for 36 months.
• ·Compensation Options exercisable at C$0.18 for 24 months.
• ·Insider participation relied on exemptions under MI 61-101.
• ·LIFE Units subject to 6-month U.S. hold period; registration statement to be filed within 5 business days.
• ·Announcement date: March 5, 2026; reverse split news releases: February 9, 2026 and March 3, 2026.

09-03-2026

Israel Acquisitions Corp amended its Form 8-K to disclose a waiver of administrative services fees to its Sponsor, including $240,000 accrued and $10,000 monthly fees until business combination or liquidation, aiding cash preservation. The filing also reveals a second amendment to the January 26, 2025 Business Combination Agreement with Gadfin Ltd. and Gadfin Regev Holdings Ltd., extending the termination date to March 16, 2026 while removing prior automatic extensions. These updates indicate ongoing efforts to complete the merger amid delays.

• ·Original BCA dated January 26, 2025; first amendment July 2, 2025
• ·Class A ordinary shares par value $0.0001; warrants exercise price $11.50 per share
• ·Securities trade on OTC Markets: ISLUF (units), ISRLF (shares), ISLWF (warrants)

09-03-2026

W&T Offshore announced preliminary unaudited FY2025 results with revenues declining 4.5% YoY to $501.5M from $525.3M and Adjusted EBITDA falling 15.6% to $129.6M from $153.6M, driven by lower realized oil ($64.09/Bbl vs $75.28) and NGL prices despite a 47% rise in natural gas prices ($3.90/Mcf vs $2.65) and slight production growth to 34.0 MBoe/d from 33.3 MBoe/d. Net loss widened to $150.1M ($(1.01)/share) from $87.1M ($(0.59)/share), but net cash from operations increased 29.7% to $77.2M, Free Cash Flow dropped sharply to $1.5M from $44.9M, and Net Debt decreased $73.9M to $210.3M. Proved reserves fell 4.7% to 121.0 MMBoe from 127.0 MMBoe, with PV-10 down 9% to $1.1B from $1.2B.

• ·Q1 2026 dividend declared at $0.01/share, payable March 26, 2026 to record March 19, 2026.
• ·Year-end 2025 proved reserves: 71% PDP, 24% PDNP, 5% PUD; 42% liquids (32% oil, 10% NGLs), 58% natural gas; reserve life ratio 9.8 years.
• ·Entered oil hedges in Jan/Feb 2026: collars for 2,000 Bbls/d Mar-Dec 2026 ($55.35-$68.60 and $57.00-$70.20 floors/ceilings), swap 2,000 Bbls/d Apr-Dec 2026 at $64.53/Bbl.
• ·Expects to file 10-K by March 16, 2026.
• ·U.S. DOI proposed changes to BOEM supplemental financial assurance rule on March 5, 2026, with 60-day comment period.

09-03-2026

News Corporation disclosed via 8-K information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1B stock repurchase program authorizing purchases of Class A (NWSA) and Class B (NWS) common stock. The disclosures, dated as noted in Exhibits 99.1 and 99.2, include forward-looking statements on potential repurchases subject to market conditions and regulations. No specific repurchase volumes or amounts were detailed in the filing.

• ·Date of earliest event reported: March 6, 2026
• ·Filing signed and dated: March 9, 2026

09-03-2026

Jefferies Financial Group Inc. filed a Form 8-K on March 9, 2026, reporting an event dated October 8, 2025, under Item 7.01 Regulation FD Disclosure, announcing the issuance of a press release attached as Exhibit 99.1. The filing includes standard registrant details and lists of registered securities but provides no financial metrics, performance data, or period comparisons.

• ·Date of earliest event reported: October 8, 2025
• ·Registrant address: 520 Madison Ave., New York, New York 10022
• ·Telephone number: 212-284-2300
• ·Commission File Number: 001-05721
• ·IRS Employer Identification No.: 13-2615557

09-03-2026

Alexander’s, Inc. (NYSE: ALX) entered into an agreement to sell its unencumbered Rego Park I property in Queens, New York, to Northwell Health, Inc., for a gross purchase price of $235.5M and net proceeds of $202M, expecting a financial statement gain of approximately $147M. The 338,000 sq ft vacant structure on 5.9 acres, built in 1959 with a 1,236-space parking garage, was recently vacated by relocating tenants to adjacent Rego Park II. The sale is subject to customary closing conditions and expected to close by Q3 2026.

• ·Rego Park I located at intersection of Queens Boulevard and Junction Boulevard, adjacent to Long Island Expressway
• ·Property built in 1959 as three-story vacant structure
• ·Tenants relocated to adjacent Rego Park II shopping center
• ·Contact phone: (201) 587-8541

09-03-2026

enGene Holdings Inc. reported a widened net loss of $29.8M for the three months ended January 31, 2026, up 21% YoY from $24.6M, driven by increased R&D expenses ($22.3M, +11%) and G&A expenses ($8.9M, +35%), with operating cash use rising to $28.9M from $25.7M. However, the company raised $126.3M gross from a public offering and $23.2M from pre-funded warrants, plus $25M from a Second Amended Term Loan, boosting total assets to $337.1M (up 52% QoQ from $221.5M) and shareholders' equity to $281.5M (up 68% QoQ). Cash and equivalents declined to $36.6M amid heavy investments in marketable securities.

• ·Loss per share improved to $0.44 from $0.48 YoY due to increased share count.
• ·Weighted-average shares outstanding: 67.3M in 2026 vs 51.0M in 2025.
• ·Marketable securities short-term increased to $239.3M from $143.6M QoQ.

09-03-2026

On March 9, 2026, Duke Energy Corporation announced the launch of a private placement of $1,000,000,000 principal amount of its Convertible Senior Notes due 2029 via a press release filed as Exhibit 99.1. The filing details the company's registered securities, including common stock (DUK) and various notes and preferred stock. No financial performance metrics, period comparisons, or other quantitative results were disclosed.

• ·Filing includes Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits).
• ·Registrant's address: 525 South Tryon Street, Charlotte, North Carolina 28202-1803.
• ·Telephone: (800) 488-3853.

09-03-2026

Boundless Bio reported Q4 and FY 2025 financial results with reduced R&D expenses (Q4: $9.8M vs $13.3M YoY, -26%; FY: $44.8M vs $55.3M, -19%) and net losses (Q4: $12.9M vs $16.4M, -21%; FY: $58.2M vs $65.4M, -11%), alongside a $108M cash position providing runway into H2 2028. The company opened enrollment in the KOMODO-1 trial for BBI-940 after FDA IND acceptance, but announced cessation of enrollment in the POTENTIATE trial of BBI-355 and BBI-825 due to prioritization. Cash decreased to $107.6M from $152.1M at end-2024.

• ·Total operating expenses Q4 2025: $14.0M vs $18.3M Q4 2024 (-23%)
• ·Total operating expenses FY 2025: $63.6M vs $73.3M FY 2024 (-13%)
• ·Net loss per share FY 2025: $(2.60) vs $(3.85) FY 2024
• ·Accumulated deficit as of Dec 31, 2025: $259.7M (up from $201.5M at end-2024)
• ·Working capital as of Dec 31, 2025: $97.1M (down from $146.3M at end-2024)

09-03-2026

Cartesian Therapeutics reported total revenues of $2.8M for 2025, down 93% YoY from $38.9M, primarily due to a 99% drop in collaboration and license revenue to $0.4M, though grant revenue increased significantly to $2.4M. Operating expenses surged 77% to $146.2M, driven by a $56.7M impairment charge on the Descartes-08 for SLE intangible asset (up from $7.6M), R&D expenses up 29% to $58.0M, and G&A up 4% to $31.5M, resulting in a widened net loss of $130.3M (68% worse) and basic EPS of ($5.02). Cash and equivalents declined to $125.1M from $212.6M, with net cash decrease of $87.4M including $73.9M used in operations.

• ·In-process R&D assets declined to $93.9M from $150.6M as of Dec 31, 2025.
• ·Goodwill stable at $48.2M as of Dec 31, 2025.
• ·Stockholders’ deficit deepened to ($126.2M) from ($6.8M).
• ·Basic net loss per share ($5.02) vs ($4.48) YoY.
• ·CVR fair value loss of $4.4M in 2025.

09-03-2026

iBio, Inc. announced preclinical data from a small, not statistically powered obese non-human primate study, where IBIO-610 reduced visceral fat by 6.7% and total fat mass by 5.2% after two once-every-eight-week doses, with only a slight up-tick in lean mass, supporting its fat-selective profile. However, the study's limited size prevents statistical significance. The company also updated its corporate presentation to highlight strategic expansion into the cardiopulmonary space, targeting pulmonary hypertension heart failure with preserved ejection fraction (PH-HFpEF) via its myostatin x Activin A bispecific antibody program.

• ·Preclinical study dosed IBIO-610 once-every-eight-weeks for two administrations
• ·Fat-selective effects consistent with other Activin E pathway approaches in rodents and human trials
• ·Press release dated March 9, 2026 (Exhibit 99.1); Corporate presentation dated March 9, 2026 (Exhibit 99.2)

09-03-2026

Editas Medicine reported a significantly narrowed Q4 2025 net loss of $5.6M ($0.06/share) from $45.4M ($0.55/share) in Q4 2024 and full-year 2025 net loss of $160.1M ($1.80/share) from $237.1M ($2.88/share), driven by sharp R&D expense cuts to $27.4M (Q4) and $90.0M (FY) following reni-cel discontinuation; however, Q4 collaboration revenues declined 19% to $24.7M from $30.6M, cash dropped 46% to $146.6M from $269.9M, and FY restructuring charges rose to $60.7M from $12.2M. The company advanced lead candidate EDIT-401, showing >90% mean LDL-C reduction in preclinical studies, with IND/CTA submission on track for mid-2026 and first-in-human HeFH trial data by year-end 2026, supported by cash runway into Q3 2027.

• ·Preparing to present additional preclinical data for EDIT-401 by mid-2026.
• ·Plans to participate in Barclays 28th Annual Global Healthcare Conference on March 12, 2026.
• ·R&D expenses Q4 decreased $21.2M YoY primarily due to reni-cel discontinuation.
• ·G&A expenses decreased $5.0M YoY in Q4 and $22.1M in FY due to workforce reduction.

09-03-2026

Fluor Corporation's Executive Chairman David E. Constable announced his retirement effective May 6, 2026, coinciding with the annual stockholders' meeting, with James T. Hackett appointed as the new Board Chair effective May 5, 2026. The company entered a one-year consulting agreement with Constable for $525,200, payable quarterly starting May 6, 2026. The Board also expanded to 12 members and elected independent director Robert G. Card, assigning him to the Audit Committee and Commercial Strategies and Operational Risk Committee.

• ·Board elected Robert G. Card effective March 4, 2026; determined independent under NYSE standards.
• ·Consulting agreement dated March 4, 2026; full text to be filed in Q1 2026 10-Q.
• ·Annual stockholders' meeting scheduled for May 6, 2026.